{"id":"NCT04475432","sponsor":"Tarsus Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","officialTitle":"Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-09-09","primaryCompletion":"2021-05-04","completion":"2021-05-04","firstPosted":"2020-07-17","resultsPosted":"2023-12-21","lastUpdate":"2023-12-21"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Blepharitis"],"interventions":[{"type":"DRUG","name":"TP-03, 0.25%","otherNames":["Lotilaner ophthalmic solution, 0.25%"]},{"type":"DRUG","name":"TP-03 Vehicle","otherNames":[]}],"arms":[{"label":"Active","type":"EXPERIMENTAL"},{"label":"Control","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.","primaryOutcome":{"measure":"Proportion of Participants Cured Based on a Collarette Score at Day 43.","timeFrame":"43 days","effectByArm":[{"arm":"Active","deltaMin":0.439,"sd":0.034},{"arm":"Control","deltaMin":0.072,"sd":0.018}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["35965392"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":212},"commonTop":["Instillation site pain","Visual acuity reduced","Instillation site pruritus","Eye pain","Eye discharge"]}}